bay2586116
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 3, 2020 (NCT04236440)
Timeline
Indications
Studied for
Mechanism of action
KCNK3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05527457 | Phase 1 | Sep 30, 2022 | Bayer, Flinders University |
| NCT04872387 | Phase 1 | May 11, 2021 | Bayer |
| NCT04713826 | Phase 2 | Mar 3, 2021 | Bayer |
| NCT04236440 | Phase 2 | Feb 3, 2020 | Bayer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 4 | 3 | 2 | 2020 |
| Flinders University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1